Which has preferable earnings & valuation, BPTSY or ORGS?

Biophytis has higher earnings, but lower revenue than Orgenesis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biophytis N/A N/A -$18.43M N/A N/A Orgenesis $662K 0.26 -$55.36M -$11.51 N/A

Is BPTSY or ORGS more profitable?

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Biophytis N/A N/A N/A Orgenesis -3,827.81% N/A -130.18%

Do analysts rate ORGS or JAGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Jaguar Animal Health 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ORGS or JAGX more profitable?

Jaguar Animal Health has a net margin of -187.88% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Jaguar Animal Health -187.88% N/A -131.45%

Is ORGS or SRNE more profitable?

Sorrento Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% Sorrento Therapeutics N/A N/A N/A

Do analysts recommend CERO or ORGS?

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 249,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CERo Therapeutics is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CERo Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CERO or ORGS more profitable?

CERo Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets CERo Therapeutics N/A N/A -209.40% Orgenesis -3,827.81% N/A -130.18%

Do analysts prefer PRPH or ORGS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is PRPH or ORGS more profitable?

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity. Company Net Margins Return on Equity Return on Assets ProPhase Labs -825.01% -482.05% -88.90% Orgenesis -3,827.81% N/A -130.18%

Orgenesis (ORGS) Competitors

$0.03 -0.32 (-90.66%)

As of 09/3/2026 10:07 AM Eastern

Compare

ORGS vs. BPTSY, JAGX, SRNE, CERO, and PRPH

Should you buy Orgenesis stock or one of its competitors? Orgenesis's main competitors and comparable companies include Biophytis (BPTSY), Jaguar Animal Health (JAGX), Sorrento Therapeutics (SRNE), CERo Therapeutics (CERO), and ProPhase Labs (PRPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Orgenesis compare to Biophytis?

Biophytis (NASDAQ:BPTSY) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Biophytis has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Biophytis	N/A	N/A	N/A
Orgenesis	-3,827.81%	N/A	-130.18%

Biophytis has higher earnings, but lower revenue than Orgenesis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biophytis	N/A	N/A	-$18.43M	N/A	N/A
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A

Biophytis has a beta of 2.46, suggesting that its share price is 146% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, suggesting that its share price is 216% more volatile than the broader market.

0.1% of Biophytis shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 3.7% of Biophytis shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Biophytis' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
Biophytis	Neutral
Orgenesis	Neutral

Summary

Biophytis beats Orgenesis on 4 of the 7 factors compared between the two stocks.

How does Orgenesis compare to Jaguar Animal Health?

Orgenesis (NASDAQ:ORGS) and Jaguar Animal Health (NASDAQ:JAGX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 12.0% of Jaguar Animal Health shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 0.2% of Jaguar Animal Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Jaguar Animal Health has higher revenue and earnings than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A
Jaguar Animal Health	$11.51M	0.31	-$53.43M	-$248.88	N/A

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Jaguar Animal Health'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Jaguar Animal Health	Neutral

Jaguar Animal Health has a net margin of -187.88% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Jaguar Animal Health	-187.88%	N/A	-131.45%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Jaguar Animal Health	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Orgenesis has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, Jaguar Animal Health has a beta of -0.07, indicating that its stock price is 107% less volatile than the broader market.

Summary

Jaguar Animal Health beats Orgenesis on 6 of the 11 factors compared between the two stocks.

How does Orgenesis compare to Sorrento Therapeutics?

Orgenesis (NASDAQ:ORGS) and Sorrento Therapeutics (NASDAQ:SRNE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled Sorrento Therapeutics'average media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
Sorrento Therapeutics	Neutral

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Orgenesis has higher earnings, but lower revenue than Sorrento Therapeutics. Sorrento Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A
Sorrento Therapeutics	$60.32M	0.01	-$572.84M	-$0.17	N/A

Sorrento Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
Sorrento Therapeutics	N/A	N/A	N/A

Orgenesis has a beta of 3.16, indicating that its stock price is 216% more volatile than the broader market. Comparatively, Sorrento Therapeutics has a beta of 0.11, indicating that its stock price is 89% less volatile than the broader market.

Summary

Orgenesis and Sorrento Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Orgenesis compare to CERo Therapeutics?

CERo Therapeutics (NASDAQ:CERO) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 1.9% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CERo Therapeutics had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for CERo Therapeutics and 0 mentions for Orgenesis. CERo Therapeutics' average media sentiment score of 0.05 beat Orgenesis' score of 0.00 indicating that CERo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
CERo Therapeutics	Neutral
Orgenesis	Neutral

CERo Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Orgenesis	-3,827.81%	N/A	-130.18%

CERo Therapeutics has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30M	-$9.84	N/A
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A

CERo Therapeutics has a beta of 0.18, suggesting that its stock price is 82% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market.

CERo Therapeutics currently has a consensus price target of $30.00, suggesting a potential upside of 249,900.00%. Given CERo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe CERo Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CERo Therapeutics beats Orgenesis on 9 of the 13 factors compared between the two stocks.

How does Orgenesis compare to ProPhase Labs?

ProPhase Labs (NASDAQ:PRPH) and Orgenesis (NASDAQ:ORGS) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

ProPhase Labs has higher revenue and earnings than Orgenesis. ProPhase Labs is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06M	0.07	-$53.36M	-$2.25	N/A
Orgenesis	$662K	0.26	-$55.36M	-$11.51	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
ProPhase Labs	Neutral
Orgenesis	Neutral

ProPhase Labs has a beta of 0.06, suggesting that its stock price is 94% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.16, suggesting that its stock price is 216% more volatile than the broader market.

ProPhase Labs has a net margin of -825.01% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ProPhase Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Orgenesis	-3,827.81%	N/A	-130.18%

9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 9.6% of ProPhase Labs shares are owned by insiders. Comparatively, 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

ProPhase Labs beats Orgenesis on 7 of the 12 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$169K	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	0.00	787.27	273.29	25.25
Price / Sales	0.26	755.95	621.79	97.64
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	0.00	12.31	13.08	6.14
Net Income	-$55.36M	$2.82B	$3.47B	$349.01M
7 Day Performance	N/A	2.59%	0.52%	-0.31%
1 Month Performance	N/A	6.95%	5.63%	0.64%
1 Year Performance	N/A	9.44%	25.31%	14.83%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.03 -90.7%	N/A	-78.2%	$169K	$662K	N/A	150
BPTSY Biophytis	N/A	$0.25 flat	N/A	N/A	$586K	N/A	N/A	30
JAGX Jaguar Animal Health	0.1172 of 5 stars	$0.92 -0.6%	N/A	-98.8%	$558K	$27.79M	N/A	50	Positive News
SRNE Sorrento Therapeutics	N/A	$0.00 +28.6%	N/A	-88.0%	$496K	$60.32M	N/A	800	Gap Down
CERO CERo Therapeutics	1.4203 of 5 stars	$0.01 +13.8%	$30.00 +329,570.3%	-99.8%	$411K	N/A	N/A	8	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors

ORGS vs. BPTSY, JAGX, SRNE, CERO, and PRPH

How does Orgenesis compare to Biophytis?

Summary

How does Orgenesis compare to Jaguar Animal Health?

Summary

How does Orgenesis compare to Sorrento Therapeutics?

Summary

How does Orgenesis compare to CERo Therapeutics?

Summary

How does Orgenesis compare to ProPhase Labs?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orgenesis (ORGS) Competitors

ORGS vs. BPTSY, JAGX, SRNE, CERO, and PRPH

How does Orgenesis compare to Biophytis?

Is BPTSY or ORGS more profitable?

Which has preferable earnings & valuation, BPTSY or ORGS?

Which has more risk and volatility, BPTSY or ORGS?

Do institutionals and insiders hold more shares of BPTSY or ORGS?

Does the media favor BPTSY or ORGS?

Summary

How does Orgenesis compare to Jaguar Animal Health?

Do insiders and institutionals believe in ORGS or JAGX?

Which has higher valuation & earnings, ORGS or JAGX?

Does the media refer more to ORGS or JAGX?

Is ORGS or JAGX more profitable?

Do analysts rate ORGS or JAGX?

Which has more risk & volatility, ORGS or JAGX?

Summary

How does Orgenesis compare to Sorrento Therapeutics?

Does the media refer more to ORGS or SRNE?

Do institutionals and insiders have more ownership in ORGS or SRNE?

Which has higher earnings and valuation, ORGS or SRNE?

Is ORGS or SRNE more profitable?

Which has more risk & volatility, ORGS or SRNE?

Summary

How does Orgenesis compare to CERo Therapeutics?

Do insiders & institutionals hold more shares of CERO or ORGS?

Does the media favor CERO or ORGS?

Is CERO or ORGS more profitable?

Which has better valuation and earnings, CERO or ORGS?

Which has more volatility & risk, CERO or ORGS?

Do analysts recommend CERO or ORGS?

Summary

How does Orgenesis compare to ProPhase Labs?

Which has preferable valuation and earnings, PRPH or ORGS?

Do analysts prefer PRPH or ORGS?

Does the media favor PRPH or ORGS?

Which has more volatility and risk, PRPH or ORGS?

Is PRPH or ORGS more profitable?

Do insiders and institutionals believe in PRPH or ORGS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools